Biomerica, Inc.

NasdaqCM:BMRA Stock Report

Market Cap: US$5.7m

Biomerica Management

Management criteria checks 3/4

Biomerica's CEO is Zack Irani, appointed in Apr 1997, has a tenure of 27.75 years. total yearly compensation is $360.10K, comprised of 41.7% salary and 58.3% bonuses, including company stock and options. directly owns 6.07% of the company’s shares, worth $347.09K. The average tenure of the management team and the board of directors is 4.1 years and 7.6 years respectively.

Key information

Zack Irani

Chief executive officer

US$360.1k

Total compensation

CEO salary percentage41.7%
CEO tenure27.8yrs
CEO ownership6.1%
Management average tenure4.1yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Dec 20
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Aug 31
Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Mar 04
We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Sep 29

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Sep 09

Biomerica reports FY results

Aug 29

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Jul 14

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Dec 03
Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Dec 02
Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep 15

Biomerica (BMRA) Investor Presentation - Slideshow

Jun 14

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Jun 13
Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Apr 04
Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Mar 08
Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Feb 10
Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Jan 15
The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica soars as its COVID-19 antigen test wins European nod

Jan 12

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Dec 20
When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Biomerica clinical trial for IBS nears enrollment completion

Dec 09

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Nov 23
How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

CEO Compensation Analysis

How has Zack Irani's remuneration changed compared to Biomerica's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-US$6m

May 31 2024US$360kUS$150k

-US$6m

Feb 29 2024n/an/a

-US$6m

Nov 30 2023n/an/a

-US$6m

Aug 31 2023n/an/a

-US$6m

May 31 2023US$141kUS$141k

-US$7m

Feb 28 2023n/an/a

-US$7m

Nov 30 2022n/an/a

-US$6m

Aug 31 2022n/an/a

-US$5m

May 31 2022US$491kUS$135k

-US$5m

Feb 28 2022n/an/a

-US$4m

Nov 30 2021n/an/a

-US$7m

Aug 31 2021n/an/a

-US$7m

May 31 2021US$488kUS$137k

-US$7m

Feb 28 2021n/an/a

-US$6m

Nov 30 2020n/an/a

-US$5m

Aug 31 2020n/an/a

-US$4m

May 31 2020US$330kUS$137k

-US$2m

Feb 29 2020n/an/a

-US$3m

Nov 30 2019n/an/a

-US$2m

Aug 31 2019n/an/a

-US$2m

May 31 2019US$329kUS$137k

-US$2m

Feb 28 2019n/an/a

-US$2m

Nov 30 2018n/an/a

-US$2m

Aug 31 2018n/an/a

-US$2m

May 31 2018US$295kUS$137k

-US$1m

Compensation vs Market: Zack's total compensation ($USD360.10K) is below average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.

CEO

Zack Irani (58 yo)

27.8yrs

Tenure

US$360,103

Compensation

Mr. Zackary S. Irani, also known as Zack, has been Chief Executive Officer of Biomerica Inc. since April 29, 1997 and is its Director and served as its President. He was Chairman of the Board at Biomerica...

Leadership Team

NamePositionTenureCompensationOwnership
Zackary Irani
CEO & Director27.8yrsUS$360.10k6.07%
$ 347.1k
Allen Barbieri
Executive Vice-Chairman of the Board & Corporate Secretary25.3yrsUS$243.98k0.47%
$ 26.6k
Gary Lu
Principal Accounting Officer & CFO1.8yrsUS$385.64k0%
$ 0
Lucy Liu
Director of Manufacturing & Technical Operationsno datano datano data

4.1yrs

Average Tenure

58yo

Average Age

Experienced Management: BMRA's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zackary Irani
CEO & Directorno dataUS$360.10k6.07%
$ 347.1k
Allen Barbieri
Executive Vice-Chairman of the Board & Corporate Secretary25.3yrsUS$243.98k0.47%
$ 26.6k
Edward Barnholt
Chairman of Strategic Advisory Board8.5yrsno datano data
Harry Leider
Member of Strategic Advisory Board6.8yrsno datano data
Douglas Drossman
Member of the Scientific Advisory Boardno datano datano data
William Chey
Member of the Scientific Advisory Boardno datano datano data
Jane Emerson
Independent Director17.8yrsUS$137.71k0.42%
$ 24.1k
Anthony Lembo
Member of Scientific Advisory Board8.5yrsno datano data
David Moatazedi
Independent Director2.1yrsUS$157.82k0%
$ 0
Catherine Coste
Independent Director4.3yrsUS$145.21k0.26%
$ 14.9k
Brooks Cash
Chairman of Colorectal Screening Scientific Advisory Board3.2yrsno datano data
William Whitehead
Member of the Scientific Advisory Boardno datano datano data

7.6yrs

Average Tenure

66yo

Average Age

Experienced Board: BMRA's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 17:11
End of Day Share Price 2025/01/03 00:00
Earnings2024/08/31
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biomerica, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Andrew D'SilvaB. Riley Securities, Inc.
Kyle BauserColliers Securities